This is an old revision of the document!
Eli Lilly
Eli Lilly & Company is an American pharmaceutical company based in Indianapolis, Indiana.
History
Bush Family
Portfolio
Eli Lilly has an exclusive worldwide licensing agreement with Centrexion Therapeutics for CNTX-0290, a novel, small molecule somatostatin receptor type 4 (SSTR4) agonist. At the time of the deal, it was in clinical trials as a potential non-opioid treatment for chronic pain conditions.1)
COVID-19
Eli Lilly has Emergency Use Authorization from the U.S. Food and Drug Administration for three experimental COVID-19 drugs: Bamlanivimab, Etesevimab and Olumiant (in combination with remdesivir).2) 3)
Eli Lilly partnered with Amgen to manufacture their COVID-19 antibody therapy products.4) Eli Lilly is also part of the COVID-19 Therapeutics Accelerator funded by the Bill & Melinda Gates Foundation, Wellcome Trust, and Mastercard to “accelerate treatments, vaccines, and diagnostics.”5)
1)
Taylor, M., Hern, K., Normart, J., & Dugan, C. (2019, May 28). Lilly Announces Licensing Agreement for Non-Opioid Pain Asset from Centrexion Therapeutics. Eli Lilly. https://investor.lilly.com/news-releases/news-release-details/lilly-announces-licensing-agreement-non-opioid-pain-asset
2)
O’Shaughnessy, J. A., PhD. (2021, December 3). RE: Emergency Use Authorization 094. Eli Lilly. Retrieved December 6, 2021, from
http://pi.lilly.com/eua/bam-and-ete-eua-fda-authorization-letter.pdf
3)
Hinton, D. M. (2021, July 28). Baricitinib EUA FDA Authorization Letter. Eli Lilly. Retrieved December 6, 2021, from
http://pi.lilly.com/eua/baricitinib-eua-fda-authorization-letter.pdf
4)
Taylor, M., & Rowland, T. (2020, September 17). Lilly and Amgen Announce Manufacturing Collaboration for COVID-19 Antibody Therapies. Amgen. https://archive.ph/pXXV5
5)
Staines, R. (2020, March 26). Pharma giants including Novartis collaborate on COVID-19 therapies. Pharmaphorum; Pharmaphorum Media Limited. https://archive.ph/8TAzM